DIVISLAB

Divi's Laboratories Share Price Divi's Laboratories

₹3,815.1
+1.3 (0.03%)
  • Advice
  • Hold
25 April, 2024 09:51 BSE: 532488 NSE: DIVISLABISIN: INE361B01024

Start SIP in Divi's Laboratories

Start SIP

Divi's Laboratories Performance

Day Range

  • Low 3,802
  • High 3,841
₹ 3,815

52 Week Range

  • Low 3,051
  • High 4,074
₹ 3,815
  • Open Price3,834
  • Previous Close3,814
  • Volume90211

Divi's Laboratories Share Price

  • Over 1 Month +11.39%
  • Over 3 Month +4.9%
  • Over 6 Month +9.18%
  • Over 1 Year +19.71%

Divi's Laboratories Key Statistics

P/E Ratio 73.2
PEG Ratio -1.7
Market Cap Cr 101,279
Price to Book Ratio 7.9
EPS 68.1
Dividend 0.8
Relative Strength Index 62.2
Money Flow Index 64.16
MACD Signal 45.97
Average True Range 76.81
Divi's Laboratories Financials
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 1,8081,8681,7301,908
Operating Expenses Qtr Cr 1,3171,3941,2391,419
Operating Profit Qtr Cr 491474491489
Depreciation Qtr Cr 95949387
Interest Qtr Cr 0100
Tax Qtr Cr 132122133149
Net Profit Qtr Cr 358342345319
IndicatorMar 2023
Total Revenue Annual Cr 7,974
Operating Expenses Annual Cr 5,278
Operating Profit Annual in Cr 2,348
Depreciation Cr 342
Interest Annual Cr 1
Tax Annual Cr 546
Net Profit Annual Cr 1,808
IndicatorMar 2023
Cash from Operating Activity Annual Cr 2,448
Cash from Investing Activity Annual Cr -2,707
Cash from Financing Annual Activity Cr -797
Net Cash Flow Annual Cr -1,055
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 12,705
Fixed Assets Annual Cr 4,931
Total Non Current Assets Annual Cr 5,116
Total Current Assets Annual Cr 9,235
Total Assets Annual Cr 14,352
IndicatorMar 2023
Book Value Per Share Annual Rs 479
ROE Annual % 14
ROCE Annual % 18
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 35
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 1,8551,9091,7781,951
Operating Expenses Qtr Cr 1,3661,4301,2741,463
Operating Profit Qtr Cr 489479504488
Depreciation Qtr Cr 95959387
Interest Qtr Cr 0100
Tax Qtr Cr 131121136146
Net Profit Qtr Cr 358348356321
IndicatorMar 2023
Total Revenue Annual Cr 8,112
Operating Expenses Annual Cr 5,400
Operating Profit Annual in Cr 2,368
Depreciation Cr 343
Interest Annual Cr 1
Tax Annual Cr 545
Net Profit Annual Cr 1,823
IndicatorMar 2023
Cash from Operating Activity Annual Cr 2,460
Cash from Investing Activity Annual Cr -2,708
Cash from Financing Annual Activity Cr -797
Net Cash Flow Annual Cr -1,045
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 12,767
Fixed Assets Annual Cr 4,934
Total Non Current Assets Annual Cr 5,127
Total Current Assets Annual Cr 9,312
Total Assets Annual Cr 14,439
IndicatorMar 2023
Book Value Per Share Annual Rs 481
ROE Annual % 14
ROCE Annual % 18
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 35

Divi's Laboratories Technicals

EMA & SMA

Current Price
₹3,815.1
+1.3 (0.03%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹3,690.81
  • 50 Day
  • ₹3,650.90
  • 100 Day
  • ₹3,649.91
  • 200 Day
  • ₹3,625.98
  • 20 Day
  • ₹3,664.72
  • 50 Day
  • ₹3,613.30
  • 100 Day
  • ₹3,689.65
  • 200 Day
  • ₹3,672.38

Divi's Laboratories Resistance and Support

PIVOT
₹3,801.1
Resistance
First Resistance 3,836.65
Second Resistance 3,859.50
Third Resistance 3,895.05
RSI 62.20
MFI 64.16
MACD Single Line 45.97
MACD 54.66
Support
First Resistance 3,778.25
Second Resistance 3,742.70
Third Resistance 3,719.85

Divi's Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 503,117 27,455,095 54.57
Week 580,391 34,887,279 60.11
1 Month 637,651 36,212,200 56.79
6 Month 513,715 25,377,542 49.4

Divi's Laboratories Result Highlights

Divi's Laboratories Synopsis

NSE-Medical-Generic Drugs

Divi's Lab is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 7625.30 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2023. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
Market Cap 101,245
Sales 7,314
Shares in Float 12.74
No of funds 725
Yield 0.79
Book Value 7.97
U/D Vol ratio 1
LTDebt / Equity
Alpha -0.02
Beta 0.78

Divi's Laboratories

Owner NameMar-24Dec-23Sep-23Jun-23
Promoters 51.92%51.92%51.93%51.93%
Mutual Funds 14.28%13.72%13.62%13.2%
Insurance Companies 7.24%7.21%7.17%6.91%
Foreign Portfolio Investors 14.68%14.85%14.6%14.69%
Financial Institutions/ Banks 0.22%0.18%0.12%
Individual Investors 8.68%8.85%9.02%9.27%
Others 3.2%3.23%3.48%3.88%

Divi's Laboratories Management

Name Designation
Dr. Ramesh B V Nimmagadda Non Exe.Chairman&Ind.Director
Dr. Murali K Divi Managing Director
Mr. Madhusudana Rao Divi Whole Time Director
Dr. Kiran S Divi WholeTime Director & CEO
Ms. Nilima Prasad Divi Whole Time Director
Mr. N V Ramana Executive Director
Mr. K V Chowdary Independent Director
Dr. S Ganapaty Independent Director
Mr. K V K Seshavataram Independent Director
Dr. G Suresh Kumar Independent Director
Mr. R Ranga Rao Independent Director
Prof. Sunaina Singh Independent Director

Divi's Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Divi's Laboratories Corporate Action

Date Purpose Remarks
2024-02-10 Quarterly Results
2023-11-06 Quarterly Results
2023-08-14 Quarterly Results
2023-05-20 Audited Results & Final Dividend
2023-02-03 Quarterly Results
Date Purpose Remarks
2023-08-11 FINAL Rs.30.00 per share(1500%)Final Dividend
2022-08-12 FINAL Rs.30.00 per share(1500%)Dividend

About Divi's Laboratories

Established in 1990, the Indian multinational pharmaceuticals company Divis Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs)including generic APIs, Nutraceutical Ingredients, and Custom Synthesis of the APIs providing high-quality products to over 95 countries. It is headquartered in Hyderabad, Telangana, India.

Divis Laboratories is among the world's leading manufacturers of generic APIs, offering a competitive advantage over the entire life cycle of the products. Competent in handling high-potency, high-energy reactions to fulfil the unmet needs of the big pharma customers, Divis Laboratories is the second most valuable pharmaceutical firm in India by market value.

In 1990, Divis Laboratories was founded as Divis Research Centre. Initially, the company began developing commercial techniques for the production of APIs and intermediates. In 1994, Divis Research Centre rebranded as Divis Laboratories Limited to indicate its entry into the API and intermediates manufacturing industry.

1997: The United Kingdom's SGS–Yarsley certifies Divis Laboratories as ISO–9002 compliant.
1999: The European Directorate issues a Certificate of Suitability (CoS) for the Naproxen manufactured by Divis Laboratories.
2001: London's BVQI grants Divis OHSAS–18001 Certification (for its Occupational Health and Safety Management Systems).
2003: Divis inaugurates a new research centre dubbed "DRC–Vizag".
2003: Went for IPO and was listed on the BSE, NSE, and HSE stock markets.
2007: Set up Nutraceuticals facility at Unit 2
2008: The third US-FDA examination of Choutuppal(Unit-1).
2008: The Visakhapatnam(Unit–2) is inspected by the KFDA.
2010: Letter of approval received by Divis Laboratories for the establishment and development of a new pharmaceutical ingredient manufacturing unit in SEZ at Visakhapatnam.
2016: First Anvisa (Brazil) inspection
2020: 8th USFDA inspection at unit 2.

Shareholding Pattern

In addition, public holdings account for 11.3% of the company's equity. The company's equity is held by retail and other investors to the tune of 4.6%.

Corporate Social Responsibility

Corporate Social Responsibility at Divis Laboratories consists of social programs, community service, and environmental impact awareness. Some key initiatives are mentioned below.

Child Empowerment Initiatives- 

Promoting Education
Preventive Healthcare
Empowering Women
Safe Drinking water
Swaach Bharat

Healthcare Initiatives-

Free Eye and Dental care Camps
ORT training and pulse polio campaigns
Incentives for Family Planning and awareness campaigns on HIV/ Aids, epidemics and malaria

Initiatives for Development of Village-

Laying of CC Roads in Villages
Construction of underground Drainages in Villages
Construction of Overhead Tanks
Laying of Gravel Roads from villages to Agricultural Fields
Facilitate Street lights in Villages


FINANCIAL INFORMATION

Bottom Line

The profit recorded has grown exponentially from INR 1219 crore to INR 3676 crore in 5 yrs. This is due to a substantial rise in revenue and a decrease in selling, general, and administrative costs.

Net Worth

It has grown by a whopping INR 5668.59 crore over the last 5 yrs.

 

Divi's Laboratories FAQs

What is Share Price of Divi's Laboratories ?

Divi's Laboratories share price is ₹3,815 As on 25 April, 2024 | 09:37

What is the Market Cap of Divi's Laboratories ?

The Market Cap of Divi's Laboratories is ₹101278.9 Cr As on 25 April, 2024 | 09:37

What is the P/E ratio of Divi's Laboratories ?

The P/E ratio of Divi's Laboratories is 73.2 As on 25 April, 2024 | 09:37

What is the PB ratio of Divi's Laboratories ?

The PB ratio of Divi's Laboratories is 7.9 As on 25 April, 2024 | 09:37

What does Divis Laboratories do?

Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.

Is Divis Laboratories good for the long term?

Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.

Is Divis Laboratories debt-free?

Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

Who is the owner of Divis Laboratories?

Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).

How to buy Divis Laboratory?

You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.

Q2FY23